I just submitted this question for Pourhassan on t
Post# of 148190
The present Standard of Care for Severe to Critical Covid patients is Dexamethasone, an immuno-surpressant. How can Leronlimab, an immuno-stimulant, be fairly tested for efficacy if the patients are taking Dexamethasone at the same time?
Here is a link to the most current NIH guidelines on Covid treatment of all levels of illness -
https://www.covid19treatmentguidelines.nih.go...anagement/
We knew the survival rate was going up while our CD12 trial was in progress. Dexamethasone was recommended for treatment since last June. It is used routinely now and it works at cross purposes to Leronlimab on the Immune System. I hope the FDA figures this out.
See calstang's post 81091.
"Imagine if the s/c trial was Leronlimab vs sugar water, the reduction is deaths vs sugar water, would probably be 80%."
Read More: https://investorshangout.com/post/view?id=607...z6oNzm5LI1